Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SANDIMMUNE vs ENVARSUS XR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Cyclosporine is a calcineurin inhibitor. It binds to cyclophilin, forming a complex that inhibits calcineurin, thereby blocking the dephosphorylation and nuclear translocation of NF-AT, reducing T-cell activation and cytokine production.
Calcineurin inhibitor. Binds to FKBP-12, forming a complex that inhibits calcineurin phosphatase, thereby blocking T-cell activation and IL-2 transcription.
Prophylaxis of organ rejection in kidney, liver, and heart transplants,Treatment of chronic allograft rejection in kidney, liver, and heart transplants,Severe active rheumatoid arthritis (FDA-approved),Psoriasis (FDA-approved),Off-label: atopic dermatitis, nephrotic syndrome, severe ulcerative colitis, aplastic anemia
Prophylaxis of organ rejection in kidney transplant patients,Prophylaxis of organ rejection in liver transplant patients
Initial oral dose: 10-15 mg/kg/day divided q12h, then taper to 5-10 mg/kg/day. IV dose: 5-6 mg/kg/day continuous infusion or divided q12h.
0.2 mg/kg/day orally once daily, with the morning meal, using extended-release tablets. Dose adjustments guided by trough concentrations.
Terminal elimination half-life is approximately 8.4 hours (range 6–24 hours) in adults; prolonged in patients with hepatic impairment.
Terminal half-life approximately 25-30 hours in stable renal transplant patients. Longer half-life (up to 50 hours) in patients with hepatic impairment.
Primarily hepatic via CYP3A4; undergoes extensive first-pass metabolism. Metabolites are excreted primarily in bile and feces.
Primarily hepatic via CYP3A4 and CYP3A5; also metabolized by intestinal CYP3A4.
Primarily biliary/fecal (94% of metabolites); renal elimination is minimal (<6% as unchanged drug and metabolites).
Primarily fecal (94%) with minor renal excretion (2.2% as unchanged drug). Biliary excretion is a significant route.
90–98% bound, primarily to lipoproteins and albumin.
Approximately 99% bound to erythrocytes and plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
3–5 L/kg in adults; high distribution indicates extensive tissue binding, including to erythrocytes and lymphocytes.
0.9-1.4 L/kg in renal transplant patients; large volume indicates extensive tissue distribution, particularly to red blood cells.
Oral: 30% (range 10–60%) due to extensive first-pass metabolism; IV: 100%; ophthalmic: not quantified, minimal systemic absorption.
Oral bioavailability is approximately 15-25% with the extended-release formulation; reduced by high-fat meal, so should be taken consistently on an empty stomach.
For Cr Cl < 30 m L/min: reduce dose by 25-50%. Monitor serum creatinine closely. Avoid in severe renal impairment unless benefit outweighs risk.
No specific GFR-based dose adjustment; however, due to nephrotoxicity, monitor renal function closely and reduce dose if renal impairment occurs. For patients with severe renal impairment (Cr Cl <30 m L/min), consider alternative immunosuppression.
Child-Pugh A: no adjustment. Child-Pugh B or C: reduce dose by 25-50%. Monitor cyclosporine levels and hepatic function.
In patients with mild to moderate hepatic impairment (Child-Pugh A or B), reduce dose by 25%. For severe hepatic impairment (Child-Pugh C), reduce dose by 50% and monitor trough levels closely.
Children: 10-15 mg/kg/day oral divided q12h; IV: 5-6 mg/kg/day. Adjust based on trough levels (target 100-400 ng/m L).
For pediatric kidney transplant recipients: 0.2 mg/kg/day orally once daily, with morning meal. Adjust to target trough concentrations. Safety and efficacy not established for other indications in pediatrics.
Start at low end of dosing range due to reduced renal and hepatic function. Monitor renal function and cyclosporine levels, as elderly are more susceptible to nephrotoxicity.
No specific dose adjustment; however, elderly patients may have increased susceptibility to nephrotoxicity and neurotoxicity. Use lowest effective dose, monitor renal function, and adjust based on trough levels.
Increased susceptibility to infection and possible development of lymphoma and other malignancies. Only physicians experienced in immunosuppressive therapy and management of organ transplant patients should prescribe Sandimmune.
Increased susceptibility to infection and possible development of malignancy (e.g., lymphoma, skin cancer).
Nephrotoxicity: Monitor renal function closely; dose-dependent and may progress to chronic nephropathy.,Hepatotoxicity: Elevations in liver enzymes and bilirubin.,Hypertension: Common; may require antihypertensive therapy.,Neurotoxicity: Tremor, convulsions, headache, and other neurological effects.,Hyperkalemia: Risk increases with concurrent use of potassium-sparing diuretics or ACE inhibitors.,Hypomagnesemia: Monitor magnesium levels.,Vaccinations: Live vaccines may be less effective and should be avoided.,Carcinogenesis: Increased risk of skin cancer and lymphoproliferative disorders.
Nephrotoxicity, neurotoxicity, hypertension, hyperkalemia, post-transplant diabetes mellitus, monitoring of blood concentrations required.
Hypersensitivity to cyclosporine or any component of the formulation,Concurrent use with PUVA or UVB therapy in psoriasis patients (increased risk of skin cancer),Uncontrolled hypertension or malignancy (relative for non-transplant indications)
Hypersensitivity to tacrolimus or any component of the formulation.
Avoid grapefruit and grapefruit juice. High-fat meals may reduce absorption; administer consistently with or without food. Do not take with potassium-rich foods or salt substitutes without monitoring.
Grapefruit and grapefruit juice increase tacrolimus exposure and must be avoided. High-fat meals may decrease absorption; consistency of food intake relative to dosing is recommended. Alcohol should be limited due to potential additive hepatotoxicity.
Cyclosporine is not a major human teratogen. First trimester exposure is not associated with an increased risk of major birth defects, but may increase the risk of preterm birth (28-33 weeks) and low birth weight. Second and third trimester use is associated with increased risk of gestational hypertension, preeclampsia, and fetal growth restriction. Prematurity and transient neonatal immunosuppression have been reported.
Envarsus XR (tacrolimus) is classified as FDA Pregnancy Category C. In the first trimester, there is an increased risk of congenital anomalies (e.g., cardiac, renal) based on animal studies; human data are limited but suggest a possible small increase. During the second and third trimesters, risks include intrauterine growth restriction, preterm delivery, and transient neonatal hyperkalemia and renal dysfunction. Advise women of childbearing potential to use effective contraception.
Cyclosporine is excreted into human breast milk. The milk-to-plasma ratio (M/P) ranges from 0.17 to 1.4, with an average of approximately 0.5. The relative infant dose is estimated to be less than 2% of the maternal weight-adjusted dose. Breastfeeding is generally considered acceptable if maternal levels are maintained within therapeutic range and infant is monitored for potential adverse effects (e.g., immunosuppression).
Tacrolimus is excreted into human breast milk. The milk-to-plasma ratio is approximately 0.5 (range 0.12–0.75). Infant exposure is estimated to be <1% of the maternal weight-adjusted dose, which is considered low. However, due to potential for immunosuppression and adverse effects, breastfeeding is generally not recommended unless benefits outweigh risks. Monitor infant for signs of immunosuppression.
Pregnancy induces increased volume of distribution and enhanced clearance of cyclosporine, leading to decreased trough levels. Dose adjustments may be required, especially in the second and third trimesters. Increase dose as needed to maintain therapeutic trough concentrations (typically 100-400 ng/m L, depending on indication). Postpartum, dose should be reduced back to prepregnancy levels due to return of normal clearance.
Pregnancy induces pharmacokinetic changes including increased volume of distribution, altered protein binding, and enhanced clearance of tacrolimus. Frequent monitoring of trough concentrations is essential to maintain therapeutic levels (target 5–10 ng/m L). Dose adjustments (increases of 20–50% or more) are often required, especially during the second and third trimesters. Postpartum, doses should be reduced to pre-pregnancy levels within 1–2 weeks.
Monitor trough levels 12 hours post-dose; target varies by transplant organ (e.g., 200-400 ng/m L for kidney, 250-800 ng/m L for liver early post-transplant). Adjust for hepatic dysfunction; cyclosporine is extensively metabolized by CYP3A4. Avoid live vaccines. Use with caution in renal impairment; dose reduction may be needed. Drug interactions: avoid with potassium-sparing diuretics due to hyperkalemia risk; monitor for gingival hyperplasia and hypertension.
ENVARSUS XR is an extended-release formulation of tacrolimus; conversion from immediate-release tacrolimus requires close therapeutic drug monitoring due to altered pharmacokinetics. Administer consistently with or without food to minimize variability. Avoid grapefruit products. Monitor renal function, blood pressure, electrolytes, glucose, and trough tacrolimus levels. CYP3A4/5 inducers/inhibitors significantly affect tacrolimus exposure; adjust dose accordingly. Do not crush, chew, or split tablets.
Take at the same time every day with a full glass of water, consistently with or without food.,Do not consume grapefruit or grapefruit juice; it can increase cyclosporine levels.,Report signs of infection (fever, sore throat), tremors, or changes in urine output.,Avoid live vaccines (e.g., MMR, nasal flu spray) and contact with recently vaccinated individuals.,Use sunscreen as cyclosporine may increase sensitivity to sunlight.,Do not change brand or dosage form without consulting prescriber.
Take exactly as prescribed, at the same time each day, with or without food but consistently.,Swallow whole; do not crush, chew, or break the tablet.,Avoid grapefruit and grapefruit juice.,Do not stop or change dose without consulting your doctor.,Report signs of infection (fever, sore throat), tremor, headache, changes in urination, or unusual bleeding.,Avoid live vaccines and limit sun exposure due to increased skin cancer risk.,Keep all appointments for blood tests to monitor drug levels and organ function.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SANDIMMUNE vs ENVARSUS XR, answered by our medical review team.
SANDIMMUNE is a Calcineurin Inhibitor that works by Cyclosporine is a calcineurin inhibitor. It binds to cyclophilin, forming a complex that inhibits calcineurin, thereby blocking the dephosphorylation and nuclear translocation of NF-AT, reducing T-cell activation and cytokine production.. ENVARSUS XR is a Calcineurin Inhibitor Immunosuppressant that works by Calcineurin inhibitor. Binds to FKBP-12, forming a complex that inhibits calcineurin phosphatase, thereby blocking T-cell activation and IL-2 transcription.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SANDIMMUNE and ENVARSUS XR depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SANDIMMUNE is: Initial oral dose: 10-15 mg/kg/day divided q12h, then taper to 5-10 mg/kg/day. IV dose: 5-6 mg/kg/day continuous infusion or divided q12h.. The standard adult dose of ENVARSUS XR is: 0.2 mg/kg/day orally once daily, with the morning meal, using extended-release tablets. Dose adjustments guided by trough concentrations.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SANDIMMUNE and ENVARSUS XR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SANDIMMUNE is classified as Category C. Cyclosporine is not a major human teratogen. First trimester exposure is not associated with an increased risk of major birth defects, but may increase the risk of preterm birth (2. ENVARSUS XR is classified as Category C. Envarsus XR (tacrolimus) is classified as FDA Pregnancy Category C. In the first trimester, there is an increased risk of congenital anomalies (e.g., cardiac, renal) based on anima. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.